Cabometyx (cabozantinib malate)
Cabozantinib is a small‑molecule, oral tyrosine‑kinase inhibitor (TKI). The product you’re referring to—Cabometyx—is the brand name for the malate salt of cabozantinib, which improves the drug’s solubility and stability in the gastrointestinal tract.
1. What Cabometyx Treats
| Indication (approved in the U.S.) |
Typical Use |
| Advanced renal cell carcinoma (RCC) |
First‑line or second‑line therapy, often after failure of VEGF‑targeted therapies. |
| Medullary thyroid carcinoma (MTC) |
Advanced disease that has progressed on other TKIs or when surgery is not possible. |
| Hepatocellular carcinoma (HCC) (in combination with bevacizumab) |
First‑line therapy for advanced HCC. |
| Other cancers (e.g., clear‑cell RCC after progression on VEGF therapy, certain sarcomas) |
Investigational or off‑label use. |
Mechanism of Action
Cabozantinib blocks multiple receptor tyrosine kinases involved in tumor growth, angiogenesis, and metastasis, including:
- VEGFR‑1, ‑2, ‑3
- MET (c‑MET)
- AXL
- RET, KIT, FLT3, and others
By inhibiting these pathways, Cabometyx reduces tumor vascularization and directly induces tumor cell death.
2. How It’s Taken
| Dose |
Schedule |
Comments |
| 60 mg once daily (with food) |
Daily |
Start at 60 mg; if intolerable GI side‑effects, step‑down to 40 mg for 2 weeks, then back to 60 mg. |
| Alternate schedules |
Some patients may take on an alternate‑day regimen to minimize toxicity, but this is off‑label. |
Food Interaction
Take with a meal to improve absorption, but avoid high‑fat meals which can alter the drug’s pharmacokinetics.
Dose Adjustments
- Gastrointestinal (GI) intolerance: reduce to 40 mg for 2 weeks, then resume 60 mg if tolerated.
- Severe diarrhea, hand‑foot syndrome, or hypertension: hold drug, treat symptom, then resume at lower dose.
- Hepatic impairment: use cautiously; no dose adjustment is officially recommended, but monitor liver enzymes closely.
3. Common Side‑Effects
| Class |
Typical Symptoms |
Management |
| GI |
Diarrhea, nausea, vomiting, abdominal pain |
Antidiarrheals (loperamide), antiemetics, hydration |
| Hematologic |
Fatigue, decreased appetite, anemia |
CBC monitoring, supportive care |
| Dermatologic |
Hand‑foot skin reaction, rash, dry skin |
Topical emollients, dose reduction if severe |
| Cardiovascular |
Hypertension, proteinuria |
BP control, diuretics, monitor urine protein |
| Others |
Weight loss, anorexia, dysgeusia (taste changes) |
Nutritional support, oral care |
Severe (grade ≥ 3) side‑effects—such as high‑grade hypertension, serious bleeding, or interstitial lung disease—require immediate dose interruption or discontinuation.
4. Important Precautions & Contraindications
| Issue |
Key Points |
| Hypertension |
Baseline BP, monitor at each visit; treat with antihypertensives. |
| Bleeding & Thrombosis |
Avoid NSAIDs, antiplatelet agents; monitor for bruising or bleeding. |
| Liver Function |
Monitor ALT/AST, bilirubin; avoid concomitant hepatotoxic drugs. |
| Kidney |
Monitor creatinine; dose adjustment not standard but watch for proteinuria. |
| Pregnancy / Lactation |
Category X. Avoid use; effective contraception for males/ females. |
| Drug Interactions |
CYP3A4 inhibitors (ketoconazole, ritonavir) ↑ levels → toxicity. CYP3A4 inducers (rifampin, carbamazepine) ↓ levels → reduced efficacy. Avoid concurrent use of strong inhibitors/inducers when possible. |
| QT Prolongation |
Baseline ECG; avoid QT‑prolonging drugs (e.g., macrolides, ondansetron). |
| Surgery |
Stop 2–3 weeks before major surgery to reduce bleeding risk. |
5. Monitoring Plan
| Parameter |
Frequency |
Why |
| Blood pressure |
At each visit (≥ 2×/month) |
Detect hypertension early |
| Liver enzymes, bilirubin |
Every 2–4 weeks |
Detect hepatotoxicity |
| Renal function & urinalysis |
Every 4–6 weeks |
Detect proteinuria & nephrotoxicity |
| CBC |
Every 2–4 weeks |
Check for cytopenias |
| Weight & nutritional status |
Every 4–6 weeks |
Prevent cachexia |
| Physical exam |
Every visit |
Assess skin toxicity, edema |
| Quality‑of‑life (QoL) questionnaires |
Every 6–8 weeks |
Evaluate impact on daily living |
6. Practical Tips for Patients
- Take it with a full meal (not necessarily high‑fat).
- Keep a symptom diary: note diarrhea, fatigue, skin changes.
- Stay hydrated: especially if experiencing diarrhea.
- Avoid alcohol: it can worsen liver toxicity.
- Adhere to follow‑up appointments: early detection of side‑effects improves outcomes.
- Report new symptoms immediately: especially bleeding, severe headache, chest pain, or breathing difficulties.
7. FAQ (Short Answers)
| Question |
Answer |
| What is the difference between Cabometyx and cabozantinib? |
Cabometyx is the branded formulation containing cabozantinib malate. The drug core is the same. |
| Why is it called “malate”? |
The malate salt improves the drug’s oral bioavailability. |
| Can I take it with my other meds? |
Discuss all medications with your oncologist or pharmacist—especially CYP3A4 modulators and anticoagulants. |
| Will it interfere with my fertility? |
It can be teratogenic; use effective contraception and discuss fertility preservation with your doctor. |
| How long does it take to see benefit? |
Response varies; many patients see radiologic improvement within 2–3 months, but continued monitoring is essential. |
Bottom Line
Cabometyx (cabozantinib malate) is a powerful oral TKI used for several advanced cancers. While it offers significant clinical benefit, it carries a notable risk of side‑effects that require proactive monitoring and dose adjustments. Close communication with your oncology team and diligent self‑care can help you manage toxicity and maximize treatment benefit.
If you have specific questions about your own regimen, side‑effects you’re experiencing, or interactions with other medications, please share more details so we can give you tailored guidance.